CRISPR Gene-Editing trial seeks to supercharge immune cells against incurable blood cancer
Disease control
Recruiting now
This early-stage trial is testing the safety and best dose of a new cell therapy for multiple myeloma that has returned or stopped responding to other treatments. Doctors take a patient's own immune cells, use CRISPR gene-editing technology to reprogram them to hunt down cancer c…
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC